Lepor H
Department of Urology, New York University Medical Center, New York, USA.
Urol Clin North Am. 1995 May;22(2):375-86.
Randomized double-blind placebo controlled studies have consistently demonstrated the safety and effectiveness of selective alpha 1 blockers for the treatment of clinical BPH. Selective alpha 1 blockers relieve the symptoms of prostatism and decrease bladder outlet obstruction. The advantages of this class of drugs for the medical treatment of BPH include the extremely rapid onset of action, statistically and clinically significant effects on relevant outcome measures, adverse experiences that are generally infrequent, mild, and reversible, serum PSA levels are not affected, and hypertension is also effectively treated. The long-term effectiveness of selective alpha 1 blockers has recently been reported. Prostate smooth muscle tension is mediated by the alpha 1a (previously defined as alpha 1c) AR. The pharmaceutical industry is aggressively pursuing development of alpha 1a "prostate" selective AR antagonists.
随机双盲安慰剂对照研究一直证明选择性α1受体阻滞剂治疗临床前列腺增生症的安全性和有效性。选择性α1受体阻滞剂可缓解前列腺增生症状并减轻膀胱出口梗阻。这类药物用于前列腺增生症药物治疗的优点包括起效极快、对相关结局指标有统计学和临床意义上的显著效果、不良反应通常很少见、轻微且可逆、不影响血清前列腺特异抗原（PSA）水平，还能有效治疗高血压。最近有报道称选择性α1受体阻滞剂具有长期疗效。前列腺平滑肌张力由α1a（以前定义为α1c）肾上腺素能受体介导。制药行业正在积极研发α1a“前列腺”选择性肾上腺素能受体拮抗剂。
